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Visceral leishmaniasis (VL) is one of the leading infectious diseases affecting developing countries. 
Colloidal gold-based diagnostic tests are rapid tools to detect blood/serum antibodies for VL diagnosis. 
Lack of uniformity in the performance of these tests in different endemic regions is a hurdle in early 
disease diagnosis. this study is designed to validate a serum-based dipstick test in eight centres of six 
countries, India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain with archived and fresh sera from 1003 
subjects. the dipstick detects antibodies against Leishmania donovani membrane antigens (LAg). the 
overall sensitivity and specificity of the test with 95% confidence intervals were found to be 97.10% 
and 93.44%, respectively. The test showed good sensitivity and specificity in the Indian subcontinent 
(>95%). In Brazil, Ethiopia, and Spain the sensitivity and specificity of the dipstick test (83.78–100% 
and 79.06–100%) were better as compared to the earlier reports of the performance of rK39 rapid test 
in these regions. Interestingly, less cross-reactivity was found with the cutaneous form of the disease 
in Spain, Brazil, and Sri Lanka demonstrating 91.58% specificity. This dipstick test can therefore be a 
useful tool for diagnosing VL from other symptomatically similar diseases and against cutaneous form 
of leishmaniasis.
Visceral Leishmaniasis (VL) or kala-azar is one of the world’s most neglected tropical diseases second in mortality 
and fourth in morbidity (WHO Factsheet 2018). Ninety percent of the VL affected cases are from the endemic 
regions of Bangladesh, Nepal, India, Brazil, Ethiopia, and Sudan. Even though the numbers of VL cases have 
reduced, a sequel to VL, known as post Kala-azar dermal leishmaniasis (PKDL), has been emerging in high num-
bers and is considered a potential reservoir for infection1,2. Lack of reliable and accurate diagnosis and variations 
in responsiveness to different drugs are the major hurdles in disease management. Splenic or bone marrow aspi-
ration and parasitological confirmation through microscopy is still the most prevalent test carried out to detect 
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kala-azar3,4. However, these tests are not 100% sensitive as parasites may not be detected in the sample, which 
necessarily does not signify absence of the disease5. Subsequently immunofluorescent antibody test or IFAT6, 
direct agglutination test or DAT7,8 and ELISA (enzyme-linked immunosorbent assay) were developed to detect 
VL. Even though DAT and IFAT perform well in almost all endemic areas9 they show variations in the antigen 
preparations and high level of cross reactivity. They are also time consuming, entail expertise and need high-end 
instruments which restrict them to laboratories.
Therefore, these are a far cry from being a field adaptable diagnostic method for the endemic areas10–12. In all 
the high VL burden areas, a third generation of serodiagnosis emerged with rK39 recombinant antigen based 
rapid diagnostic tests (RDTs). Owing to its ease-of-use, stability, field adaptability and performance rK39 became 
the most used tool in diagnosis of the VL. Even though rK39 performs with high sensitivity and specificity espe-
cially in India, its performance varies with a sensitivity range from 36–100% and specificities from 90.8–100% in 
East Africa and Brazil13,14 (TDR 2011,WHO). The regional discrepancies in results led to manufacturing of RDT’s 
with local, region specific antigens for example rKE16, rK28, rKLO815–17. These too have their drawbacks and are 
not the most preferred alternative to available diagnosis. Moreover, emerging PKDL cases are a challenge for the 
VL elimination program. There is no consensus on the use of serological tests for PKDL diagnosis since perfor-
mance of the antigens show heterogeneity in several studies10,18. Besides, serological tests for VL diagnosis often 
showed cross reactivity with CL patients.
A pressing need for overcoming these shortcomings led us to develop a leishmanial membrane antigens (LAg) 
based serodiagnostic dipstick test which we showed 100% sensitive and specific against Indian and Brazilian VL 
and Indian PKDL19. Unlike whole parasite antigen used in DAT, LAg contains membrane antigens of promas-
tigote thus it shows minimal cross reactivity with other diseases in comparison to broad antigen panel. With 
the severity of these diseases on the rise and the substantial variability in the results among various areas, it is a 
challenge to find a diagnostic test that can perform equivocally in all the regions. In the current study we aimed to 
determine the performance of this LAg-based diagnostic test in six global regions of VL endemicity and establish 
evidence of its specificity and sensitivity. Thus we report here a large scale global comparative study of a single 
immunochromatographic test across areas such as India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain where VL 
is either prevalent or endemic.
Results
In this multicentric study a total of 1003 sera samples in six VL endemic regions across the globe were tested over 
a period of 4 years. Out of these, 463 were confirmed VL cases, 21 PKDL cases, 184 endemic healthy control, 105 
non-endemic healthy control, 123 other symptomatically similar diseases and 107 CL cases (Table 1). The dipstick 
with two coloured bands at the test line and control line was considered positive and a single band at the control 
line was negative. A representative illustration of dipstick test is shown in Fig. 1”.
India. The blind test was conducted with archived serum samples of 143 confirmed VL cases, 11 PKDL and 57 
control samples at Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna during March 
2013 to June 2013. The tests performed well and the results of these Indian samples showed sensitivity of 98.05% 
for VL (140/143) and PKDL (11/11) cases. Out of 140 dipstick positive VL cases one sample was false negative 
with rK39 and two out of three false negative found in dipstick test were positive with rK39 test. Of the 57 control 
samples one endemic healthy control and 2 other diseases showed cross reactivity in dipstick test, thereby depict-
ing an overall 94.73% (54/57) specificity in that centre.
Blind folded dipstick test was carried out at the Institute of Postgraduate Medical Education and Research 
(IPGMER) in Kolkata on 25 archived VL cases and 25 healthy controls (endemic and non-endemic) confirmed by 




NEHC EHC Other Diseases CL
SpecificityPos Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg
IICB — — — — 0 40 — — — — — — 100
India
STM 69 1 10 0 98.75 — — 0 6 0 15 — — 100
RMRIMS 140 3 11 0 98.05 0 5 1 37 2 12 — — 94.73
IPGMER 22 2 — — 91.66 0 10 2 13 — — — — 92
Nepal BPKIHS 98 0 — — 100 0 21 8 92 2 27 — — 93.33
Sri Lanka University of Colombo 3 2 — — 60 0 13 — — 1 53 9 69 93.10
Brazil Universidade Federal do Piaui 40* 0 0 0 100 0 20* — — — — 0 20 100
Ethiopia University of Gondar 86 0 — — 100 0 16 5 11 4 7 — — 79.06
Spain Instituto de Salud Carlos III 31 6 — — 83.78 — — 0 9 — — 0 9 100
Total 449 14 21 0 97.10 0 105 16 168 09 114 9 98 93.44
Table 1. Number of samples tested with dipstick and the obtained sensitivity and specificity in each region. 
NEHC: Non-endemic healthy controls, EHC: Endemic healthy controls, CL: Cutaneous leishmaniasis; *Data 
obtained in previous study19.
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the dipstick test thus provided 91.66% (22/24) sensitivity. Two endemic healthy control samples gave false positive 
result in the dipstick test thus showed 92% (23/25) specificity.
We collected fresh blood samples from patients having symptoms of VL and were confirmed parasitologically 
at School of Tropical Medicine (STM), Kolkata. Of the samples tested, 69 out of 70 VL cases were detected in the 
dipstick test along with 10 PKDL cases with overall sensitivity of 98.75%. Interestingly, there have been instances 
(n = 5) where parasitologically confirmed VL cases showed negative results with rK39 strip test but tested positive 
with PCR and dipstick test. Six endemic healthy controls and 15 other diseases collected from STM showed no 
cross reactivity in dipstick test. Forty samples from non-endemic healthy controls were collected and tested in the 
Indian Institute of Chemical Biology (IICB), Kolkata with 100% specificity.
Nepal. To evaluate this diagnostic dipstick test in the endemic region of Nepal a blind folded test was carried 
out at the B.P. Koirala Institute of Health Sciences, Dharan, Nepal. A total of 248 tests were conducted, 98 con-
firmed VL cases, 100 endemic healthy controls, 21 non-endemic healthy control and 29 other diseases which 
were pathologically confirmed. The sensitivity of the test in Nepal was found to be 100% (98/98) without any false 
negative results (Fig. 2). The overall specificity of the test including all 150 controls was 93.33% (140/150). Eight 
endemic healthy controls and two other diseases showed cross reactivity in the dipstick test.
Figure 1. Representative picture of dipstick test with Indian kala-azar positive (1–4) and negative serum 
samples (5–8).
Figure 2. Performance of dipstick test in six countries, India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain. 
Sensitivity in Brazil depicted from previous study (*)19.
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sri Lanka. Striking results were obtained from samples tested at University of Colombo, Sri Lanka. Out of 
5 cases of autocanthous VL in Sri Lanka, dipstick showed positivity with 3 serum samples. Interestingly, in Sri 
Lanka, both VL and CL are caused by L. donovani infection. On testing 78 such CL samples our dipstick could 
identify 69 of them as negative therefore making our test highly specific for VL even if the causative agent is the 
same. With a total of 67 control samples including 13 non-endemic healthy controls, 14 other symptomatically 
similar diseases to VL such as malaria, viral fever, typhoid, pneumonia, etc. and 40 other skin diseases, dipstick 
showed cross reactivity with only one sample demonstrating an overall 98.50% (66/67) specificity of the test. 
However, including tested CL cases in the calculation showed 93.10% (135/145) specificity overall.
Brazil. Our group had previously reported (Saha et.al) 100% sensitivity and specificity of dipstick test on 60 
samples from Brazil (40 VL and 20 healthy controls). We in this study additionally tested 20 CL cases in Brazil 
infected with L. braziliensis. Brazil is amongst the seven countries reporting 90% CL cases20. None of the CL sam-
ples showed cross reactivity with L. donovani antigen, LAg, in the dipstick test. Thus dipstick did not recognize 
tegumentary form of leishmaniasis in Brazil.
ethiopia. A blind-fold study was conducted at the University of Gondar, Ethiopia. A total of 129 samples were 
tested, out of which 86 were acute VL and 43 control samples including 11 other diseases, 16 endemic healthy 
controls and 16 non-endemic healthy controls. VL cases were confirmed with bone marrow (n = 21) or splenic 
aspirates (n = 65). Our dipstick in Ethiopia showed overall 100% sensitivity and 79.06% specificity. Interestingly, 
one confirmed VL case was positive in our dipstick but negative with rK39 strip test. Out of eleven other diseases 
four samples of pneumonia, spontaneous bacterial peritonitis, abscess and one unknown disease showed positive 
results with the dipsticks. All the 16 non-endemic controls were found negative with the dipsticks. However, in 
the endemic healthy controls, 5 out of 16 were false positive. rK39 test could not be performed with the other 
diseases and endemic healthy controls to establish the serological status of the cases.
spain. A total of 55 serum samples were tested in Instituto de Salud Carlos III, Madrid, Spain, including 37 
samples of confirmed VL cases, 9 endemic healthy controls and 9 CL samples. VL cases were confirmed with 
serological test such as ELISA and IFI. PCR was done with bone marrow and peripheral blood for VL and skin 
biopsy for CL. Our dipstick tests showed positive results in 31 out of 37 confirmed VL cases thus showing 83.78% 
sensitivity. Two confirmed and dipstick positive VL cases showed negative result with IFI titre less than 1/40 and 
four VL cases with antibody titre less than 0.2 in ELISA. Seventeen dipstick positive confirmed VL cases were 
negative in PCR while eight dipstick positive VL cases were negative with rK39 strip test. However, two confirmed 
VL cases which were negative in our dipstick test were found to be positive with rK39 strip test. All the 9 endemic 
control samples were found negative in dipstick test and also in PCR and rK39 strip test. The dipstick did not 
show any cross reactivity with any of the nine CL samples. However, one serum sample in PCR and two in rK39 
test showed cross reactivity with CL.
Discussion
Herein, we report the performance of LAg, a leishmanial membrane extract, as a diagnostic marker in a dipstick 
format and validated this across six VL endemic countries for global comparative evaluation. Our LAg-based 
dipsticks were distributed amongst our collaborators situated in various VL endemic regions and unbiased test 
against 1003 samples was done for validation. Our findings illustrate a high sensitivity (97.10%) and specificity 
(93.44%) of the test in all these regions collectively.
A range of techniques are available to detect VL across the world out of which microscopy of tissue aspirates 
such as spleen and bone marrow are still the gold standard test21. However, these are invasive, have variable 
sensitivities, technician dependent and complex. Apart from microscopy several tests are available in the form 
of molecular diagnostics like PCR, serological tests such as DAT and IFAT, or rapid diagnostic tests like rK39. 
Each of these has its own advantages and disadvantages and discrepancy in results. Because of which none has 
been able to withstand as a standalone test for VL alone. DAT which uses whole parasite antigen has proved to be 
highly specific and sensitive in most of the endemic areas, and certain areas where HIV co-infection is prevalent 
for example in Spain and other parts of Europe. In fact a recent report claims the performance of DAT to be better 
than rK39 based RDTs when tested against archived samples in Spain5, moreover, it is the most cost effective test 
in Brazil9. Recently a multicentre validation of DAT showed sensitivity ranging from 96·2–99·5% and specificity 
between 96·2–97·5%22. However, due to its cumbersome process and high levels of cross reactivity with other 
trypanosomatids, rK39 based tests are preferred over DAT. rK39 recombinant antigen based diagnosis is a widely 
used RDT as it is easy to use, is highly sensitive for samples in the Indian subcontinent, and is stable. However, its 
variability in performance between regions is an area of concern especially in East Africa where its sensitivity is 
reported to be as low as 67.6%5. Our focus was therefore to make a dipstick test with the leishmanial membrane 
antigens (LAg), with the advantages of high sensitivity of DAT, along with the ease of use and robustness of RDTs 
like rK39.
For diagnosis of VL, rK39 RDT has been very well studied in the Indian subcontinent where WHO recom-
mended its use and its inclusion in national VL elimination program for diagnosis23. We previously tested our 
LAg-based dipstick in India with 100% sensitivity and specificity19. To further validate, we tested samples across 
the highly endemic regions of India that is Bihar and West Bengal. 97.67% (252/258) sensitivities and 96.50% 
(138/143) specificities were obtained at the four centres in India. Based on the study in India performance of 
dipstick is comparable with rK39 in this region.
Over the years of this study we and others18 have observed a striking increase in PKDL cases in India, which 
many a time gets confused with leprosy thus delaying treatment. Patients suspected with PKDL are usually tested 
by slit-skin smear or skin biopsy, which may fail to show the presence of parasites in lesions18. Since PKDL is a 
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reservoir for parasites, and could be the cause behind newer cases, it has become imperative for any diagnostic 
test to be able to determine these cases. Herein our dipstick showed 100% (21/21) sensitivity in detecting PKDL 
cases in India.
A pertinent problem with VL cases in Nepal is the delay in detection of the disease from the inception of 
symptoms24. Even though the number of VL cases in Nepal is decelerating, new VL cases have been reported over 
the past years in areas which were previously non-endemic25. LAg dipstick herein performs very well amongst all 
the tested samples with 100% sensitivity. Amongst the control tests, non-endemic healthy controls were detected 
with 100% specificity. However, cross reactivity amongst the endemic healthy controls and other diseases result-
ing in overall specificity of 93.33%.
Leishmaniasis in Sri Lanka is a newly emerging disease and established as a notifiable public health problem 
only after 200826. L. donovani, otherwise known to cause VL in East Africa and India, is the causative agent for 
CL in Sri Lanka27,28. We were therefore very interested in testing for any cross reactivity of our dipstick, which is 
coated with L. donovani membrane antigen. Interestingly, our dipstick test show negative results for such CL cases 
in 69 out of 78 samples. Moreover, with very few VL samples tested in Sri Lanka dipstick showed positive result 
with three out of five Sri Lankan VL tested.
Brazil has been reported with around 0.2 million VL cases and 0.7–1 million CL cases. Therefore it is extremely 
important for a diagnostic test to be able to distinctly detect VL which should not show cross reactivity espe-
cially with tegumentary leishmaniasis. We have previously shown 100 percent sensitivity and specificity of our 
LAg-dipstick in detecting VL from Brazilian serum samples19. Other than microscopy, CL has been attempted to 
be diagnosed with RDTs like rK39, but results show a lot of variability from 10–100% specificity29,30. We therefore 
checked if our dipstick test could differentiate CL from VL cases and found no cross reactivity of dipstick test with 
CL samples in Brazil.
Eastern African countries are the third most endemic areas for VL especially Ethiopia, Sudan and South 
Sudan. Like in the other endemic regions, here too, parasite detection along with DAT or rK39 is the diagnostic 
regime. Due to low level of accuracy of rK39 in these regions, local antigens like rKLO8, or newer antigens like 
rk28 have been tested. To our delight, in our study we found 100% sensitivity and 79.06% specificity of dipstick 
test in Ethiopia.
A study conducted in Spain with our LAg-based dipsticks also fared well with good sensitivity and specific-
ity. With limited number of samples the dipstick test showed its best performance in detecting VL cases when 
compared individually with other reference tests, IFI, ELISA and PCR. Dipstick was also found better in dis-
criminating CL cases than PCR and rK39 test. In a recent study, it was reported that DAT performs better than 
rk39 in samples co-infected with HIV. This could be due to the whole antigen used in DAT5. As we also utilize 
specific leishmanial membrane extracted antigen, it is possible that our dipstick can perform well amongst the 
HIV co-infected patients also, which would be an interesting study for future. In the current study antigen LAg 
was used in a dipstick format that can be applied in field settings with limitations of serum dilution and washing 
steps. To make the dipstick fully field adaptable we have transformed it into the lateral flow based rapid test which 
will be validated in the near future.
As none of tests alone is enough to confirm VL, it is suggested that two confirmatory tests be performed11. This 
study deals in the global comparison of a single test across major VL affected areas. The results are highly encour-
aging and since this study utilises the best of both DAT and RDTs it can be a single cost effective confirmatory test 
for detection of VL in the endemic areas.
Methods
study design. We aimed to test the performance of leishmanial antigens, LAg in the dipstick format across 
several VL endemic regions worldwide, thereby chose participants from eight VL endemic centres comprised of 
six different countries where 1003 samples were tested.
Antigen preparation. L. donovani membrane antigens (LAg) were prepared from cell pellets of L. donovani 
promastigote strain (ATCC® PRA-413™)19,31. In brief, cell pellets were washed three times in 0.02 M PBS and 
then suspended in hypotonic medium of 5 mM cold Tris-HCl buffer, pH 7.6 (1 g of cell pellet in 50 ml of 5 mM 
Tris–HCl). Cells were then vortexed vigorously (6 times for 2 min each with 10 min intervals in ice) to make the 
membrane surface leaky and effective release of all cytoplasmic matrix from the cells in the hypotonic medium. 
Following this, the suspension was centrifuged (2310 × g for 10 min at 4 °C) (BiofugeTMStratosTM, Heraeus, 
Germany) to obtain the ghost membrane as pellet containing membrane bound proteins. Pellets along with 10 ml 
of ice-cold Tris-HCl buffer were then sonicated with 6 cycles of 30 sec pulse and 1 min interval at 4 °C. Sonication 
dissociates the protein from the membrane and was collected in the supernatant by centrifugation (5190 × g, at 
4 °C for 30 min). Protein concentration of LAg was estimated by the Lowry’s method. A particular pattern of pre-
dominant proteins of LAg was ensured through SDS-PAGE before the dipstick preparations32.
Dipstick development and assay. Dipsticks for the assay were prepared following previous protocol as 
mentioned by Saha et.al.19 Briefly, LAg (1.0 µg/4 mm dipstick) at the test line and rabbit anti-human IgG (1:10 
dilution) at control line were coated onto a nitrocellulose membrane (8 cm × 2.4 cm). Further the membrane was 
blocked overnight with 2% BSA + 0.1% Tween-20 and 0.01% NaN3 in 100 mM Tris Buffer Saline (TBS) at 4 °C 
which was followed by washing with TBS + 0.05% Tween-20 (TBST), drying and adhering to the moisture unre-
ceptive plastic sheet, cut and stored at RT in desiccation until the test.
The assay comprises of incubation of the dipstick with diluted serum samples (1:2000) for 30 mins which is 
followed by washing with TBST (twice). Subsequently, it is incubated with HRP conjugated anti-human IgG (1: 
2000) for 30 mins. Finally, after two washes in TBST and one in TBS, the strips are dipped in a freshly prepared 
substrate composed of 0.05% 3, 3′-diaminobenzidine tetrahydrochloride (DAB, Sigma, USA) containing 0.05% 
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of H2O2 in 100 mM TBS. The reaction is stopped by dipping in distilled water. The appearance of dark brown 
coloured bands at both the test and control line indicates VL positivity and a single band at the control line is 
indicative of VL negativity.
Assay selection. Freshly prepared batches of strips quality tested with confirmed positive and confirmed 
negative VL cases were shipped to each laboratory clearly mentioning the storage conditions and shelf-life of the 
dipsticks. Each lab was sent a written protocol and a video of the test being performed by us for uniformity in 
conducting the test. Each laboratory assembled a performance panel using locally archived and depersonalized 
sera. VL was confirmed parasitologically (from spleen, bone marrow, or lymph node) by microscopy and/or cul-
ture. Healthy endemic control samples and potentially cross reactive samples were also collected and tested. The 
samples used were unknown/blind for the performer at the time of the assay which was disclosed after the test 
completion and interpretation.
Result interpretation. Test results were analyzed, interpreted and recorded blindly by at least two observers 
on standardized form from all participating regions. The final results were compiled and analysed by us to deter-
mine the sensitivity and specificity of the dipstick test in each region.
ethical statement. This study was approved by the Human Ethics committee of CSIR-Indian Institute of 
Chemical Biology. Additionally, each participating laboratory obtained local or institutional ethical clearance for 
carrying out the tests. Written informed consents were taken from each participant and methods performed in 
this study were according to the ethical guidelines.
Data Availability
All data generated or analyzed during this study are included in this published article.
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